新闻动态 News
查看更多 >>
-
2026-09-29今天的AI已经非常会回答科学问题了,但它能完成一次真实的药物研发任务吗? 9月22-24日,在阿里举办的2026云栖大会上,MolVortex回答了这个问题。MolVortex是望石智慧全新首发的全栈式小分子医药早研智能体,产品研发负责人付冬在发布时表示,MolVortex立足于打造医药垂直领域里真正具有研发能力、能够切入研发决策的AI Scientist。其能够完整覆盖小分子药物早期研发从情报分析到合成性评估全链条,遵循药物发现底层逻辑,复刻研发科学家思路,完成高效小分子药物开发。 此次发布,是望石智慧在小分子药物研发领域AI能力价值转化的一次关键突破,更标志着公司迈出了从电子尺度向更广泛微观世界机制理解的重要一步。该智能体将加速小分子药物研发领域的数智化升级,并推动研发组织形态的变革。 望石智慧产品研发负责人付冬发布全新MolVortex 研发的核心是持续的科学决策闭环 创新药物发现是一场循环往复的科学决策闭环。一次科学发现的起点,通常来源于研发人员的观察与假设,再设计候选,用合适的方法评估,决定下一步行动,进入实...
-
2026-07-21“今天上海非常热,但我感觉到人工智能甚至比上海的天气还要热。” 7月18日,2026年世界人工智能大会(WAIC)开幕第二天,在WAIC官方战略合作媒体第一财经的直播访谈中,望石智慧创始人兼CEO周杰龙这样说道。 本届WAIC以“智能伙伴,共创未来”为核心主题,聚焦AI技术从算力基建向产业纵深落地,在生物医药赛道,AI展现出破解传统研发周期长、成本高、成功率低等痛点的非凡潜力,备受各方关注。 深耕AI医药赛道八年的望石智慧,目前已成为国内AI制药领域的领军企业。周杰龙本人则已在人工智能领域探索了十余年,曾因受到家人患癌去世的触动,而决心投身医药研发,成为中国AI制药行业的“探路人”之一。 周杰龙2018年创立望石智慧后,带领团队完成了从智能药物设计平台搭建、AI药物早研智能体落地到微观分子世界模型布局的完整技术迭代。 在本次访谈中,周杰龙详细分享了望石智慧“向下扎根、向上突破”的发展逻辑,并勾勒出AI制药从降本增效到底层范式革新的产业新图景。 点击图片观看访谈完整版...
-
2026-06-086月4日,由德国海外商会联盟(AHK)大中华区主办的AHK创新之夜(AHK Innovation Night)2026在苏州成功举办,望石智慧(StoneWise)凭借全球领先的AI小分子药物研发智能体及AI赋能医药早研全链条创新成果,经过线上初赛、专家评审层层遴选,在百家参选企业中拔得头筹!望石智慧也是本届赛事唯一获奖的AI制药企业,这份荣誉印证了国际评审对望石技术实力与国际化竞争力的高度认可。 AHK中德创新之夜是中德两国高规格创新路演盛会,本次活动汇聚了200余位中德商界领袖、行业专家与投资机构代表,共探产业创新与跨境合作新机遇。活动现场,中国德国商会华东及华中地区执行董事兼董事会成员柯铭诚等代表发表欢迎辞,为本次中德创新盛会拉开帷幕。 现场,新华网以视频形式记录了盛会的精彩瞬间,并对望石智慧代表资本市场副总裁贾禹萌进行了采访。 能够在本次赛事摘得桂冠,依托于望石智慧构筑的硬核技术壁垒、成熟的产业落地能力与前瞻性的国际化视野。 历经数十年的产业演进,药物研发范式持续迭代,从依靠实操实验与科研经验的传统研发,到 CAD...
-
2026-05-205月20日,广州医药集团有限公司(下称“广药集团”)、华为技术有限公司(下称“华为”)、北京望石智慧科技有限公司(下称“望石智慧”)在广州正式签署协议,达成生态合作。广药集团副董事长、总经理陈杰辉,广药集团副总经理程洪进,华为副总裁、制造与大企业军团CEO刘超,望石智慧副总裁苏小凡出席并见证了签约。广药数科董事长邹彬彬、华为制药军团总裁樊杰代表双方签约。 此次合作,既是望石智慧与华为在生物医药赛道“灯塔项目”的首次实质落地,也是广药集团AI制药 “1+1+1” 创新模式的关键实践,标志着望石智慧助力领军医药集团数智化转型取得重要突破。三方打造的国内“产业场景+AI算法+国产算力”全链条创新体系逐步成型,为中国生物医药产业智能化、自主化升级树立标杆,注入新质生产力动能。 三方将发挥各自核心优势,构建深度协同的创新联合体。依托广药集团成熟研发场景与产业资源,望石智慧提供全球领先的小分子AI药物设计核心技术,输出AI分子设计平台Molvado与多智能体药...
-
2026-03-25近日,以“因聚而升 融智有为”为主题的华为中国合作伙伴大会2026在深圳圆满落幕。望石智慧作为其国内AI驱动医药创新领域的核心技术伙伴受邀参会,并在智能制造医药行业论坛发表演讲。会议期间,望石智慧、华为、华鲲振宇三方达成战略级生态合作,正式发布“AI药研联合解决方案”,旨在通过自主创新算力底座与全链条数智化解决方案,构建中国医药行业“第二科技平面”,推动中国医药产业迈向高质量发展新阶段。 此外,在数智医药专属展区中,望石智慧全方位展现自研AI制药领域医药技术创新成果,现场交流洽谈氛围热烈,吸引众多行业合作伙伴驻足,这既彰显了望石在数智医药领域的技术引领与市场认可,更是其在深化生态合作、赋能医药创新的生动实践。 强强联合,AI辅助药物研发融合范式重磅落地! 当前,医药产业正加速迈向数智化升级,传统药物研发周期长、成本高、算力对外依赖等痛点日益突出。将自主可控的算力支撑与成熟的AI药物研发技术平台深度融合,构建协同共生的数智医药产业生态,已成为行业破局升级的...
-
2026-03-193月18日,2026新时代品牌发展论坛暨福布斯中国行业发展领创者评选荣耀盛典在上海圆满举办。依托行业领先的技术壁垒、可规模化的落地实力,望石智慧获评“2026福布斯中国行业发展领军企业”,成为此次获奖名单中唯一的AI制药企业。该荣誉不仅是对望石智慧技术实力与产业价值的权威认可,更标志着望石智慧作为人工智能与生物医药融合创新的标杆力量,正式跻身行业主流视野。 同期获评的还包括优必选科技、海天味业、泰德医药、昆仑新能源等行业细分龙头,覆盖AI、大消费、医疗健康、新能源等关键赛道,入选企业均为各领域具备可持续发展能力的标杆力量。 本次评选由福布斯中国与全球知名增长咨询机构弗若斯特沙利文联合发起,以国家战略响应、创新表现、商业成长力、可持续发展能力、行业影响力五大核心维度为评审标准,重点考察参选主体在行业赋能、商业运营与创新实践中的表现。 望石智慧始终致力于人工智能与生物医药的深度融合,积极响应国家创新发展战略,以科技创新助力医药产业高质量升级,用实际成果践行科技赋能实体经济的发展方向。 通过多轮数据...
学术进展 Academic Progress
查看更多 >>
-
2024-07-11Weiqiang Fu, Yujie Mo, Yi Xiao, Chang Liu, Feng Zhou, Yang Wang, Jielong Zhou*, Yingsheng J. Zhang* June 3, 2024 DOI: https://doi.org/10.1021/acs.jctc.3c01181 Abstract: Exclusively prioritizing the precision of energy prediction frequently proves inadequate in satisfying multifaceted requirements. A heightened focus is warranted on assessing the rationality of potential energy curves predicted by machine learning-based force fields (MLFFs), alongside evaluating the pragmatic utility of these MLFFs. This study introduces SWANI, an optimized neural network potential stemming from the ANI framework. Through the incorporation of supplementary physical constraints, SWANI aligns more cohesively with chemical expectations, yielding rational potential energy profiles. It also exhibits superior predictive precision compared with that of the A...
-
2024-07-05Feng Zhou, Haolin Du, Yang Wang, Weiqiang Fu, Bingchen Zhao, Jielong Zhou*, Yingsheng J. Zhang. June 5, 2024 DOI: https://doi.org/10.1021/acsmedchemlett.4c00047 Abstract: We employ a combination of accelerated molecular dynamics and machine learning to unravel how the dynamic characteristics of CBL-B and C–CBL confer their binding affinity and selectivity for ligands from subtle structural disparities within their binding pockets and dissociation pathways. Our predictive model of dissociation rate constants (koff) demonstrates a moderate correlation between predicted koff and experimental IC50 values, which is consistent with experimental koff and τ-random accelerated molecular dynamics (τRAMD) results. By employing a linear regression of dissociation trajectories, we identified key amino acids in binding pockets and along the dissociati...
-
2024-01-15Wei Feng, Lvwei Wang, Zaiyun Lin, Yanhao Zhu, Han Wang, Jianqiang Dong, Rong Bai, Huting Wang, Jielong Zhou, Wei Peng, Bo Huang & Wenbiao Zhou 15 January 2024 DOI: https://doi.org/10.1038/s42256-023-00775-6 Abstract: Generative models for molecules based on sequential line notation (for example, the simplified molecular-input line-entry system) or graph representation have attracted an increasing interest in the field of structure-based drug design, but they struggle to capture important three-dimensional (3D) spatial interactions and often produce undesirable molecular structures. To address these challenges, we introduce Lingo3DMol, a pocket-based 3D molecule generation method that combines language models and geometric deep learning technology. A new molecular representation, the fragment-based simplified molecular-input lin...
-
2023-12-11Di Wu, Qihao Chen, Zhuoya Yu, Bo Huang, Jun Zhao, Yuhang Wang, Jiawei Su, Feng Zhou, Rui Yan, Na Li, Yan Zhao & Daohua Jian. 11 December 2023 DOI: https://doi.org/10.1038/s41586-023-06926-4 Abstract: Vesicular monoamine transporter 2 (VMAT2) accumulates monoamines in presynaptic vesicles for storage and exocytotic release, and has a vital role in monoaminergic neurotransmission1,2,3. Dysfunction of monoaminergic systems causes many neurological and psychiatric disorders, including Parkinson’s disease, hyperkinetic movement disorders and depression4,5,6. Suppressing VMAT2 with reserpine and tetrabenazine alleviates symptoms of hypertension and Huntington’s disease7,8, respectively. Here we describe cryo-electron microscopy structures of human VMAT2 complexed with serotonin and three clinical drugs at 3.5–2.8 &Ari...
-
2023-12-05Bo Qiang, Yiran Zhou, Yuheng Ding, Ningfeng Liu, Song Song, Liangren Zhang, Bo Huang & Zhenming Liu. 05 December 2023 DOI: https://doi.org/10.1038/s42256-023-00764-9 Abstract: Chemical reactions are the fundamental building blocks of drug design and organic chemistry research. In recent years, there has been a growing need for a large-scale deep-learning framework that can efficiently capture the basic rules of chemical reactions. In this paper, we have proposed a unified framework that addresses both the reaction-representation learning and molecule generation tasks, which allows for a more holistic approach. Inspired by the organic chemistry mechanism, we develop a new pretraining framework that enables us to incorporate inductive biases into the model. Our framework achieves state-of-the-art results in performance of challenging downstream tasks. By poss...
-
2023-11-21Lanying Wei, Yucui Xin,Mengchen Pu,Yingsheng Zhang. 17 November 2023. DOI: https://doi.org/10.26508/lsa.202302253 Abstract: To effectively understand the underlying mechanisms of disease and inform the development of personalized therapies, it is critical to harness the power of differential co-expression (DCE) network analysis. Despite the promise of DCE network analysis in precision medicine, current approaches have a major limitation: they measure an average differential network across multiple samples, which means the specific etiology of individual patients is often overlooked. To address this, we present Cosinet, a DCE-based single-sample network rewiring degree quantification tool. By analyzing two breast cancer datasets, we demonstrate that Cosinet can identify important differences in gene co-expression patterns between individual patients and g...



